Improved Accuracy and Decreased Pain Levels From Randomized Controlled Trial With MAKO's Robotic Arm System

Improved Accuracy and Decreased Pain Levels From Randomized Controlled Trial
With MAKO's Robotic Arm System

Early Results Show Patients Fare Better With Robotic Arm Surgery for Partial
Knee Resurfacing Compared to Traditional Surgery

CHICAGO, March 21, 2013 (GLOBE NEWSWIRE) -- MAKO Surgical Corp., developer of
human-interactive surgical robotic arm technology used to achieve accuracy in
treating osteoarthritic disease, today announced the first results from a
ten-year, prospective, randomized controlled trial evaluating the accuracy of
unicompartmental knee arthroplasty (UKA) implant positioning, with and without
robotic arm surgical assistance. Early results from this pivotal study are
compelling, showing that robotic arm assisted UKA enhanced the accuracy of
implant placement and decreased the levels of pain.

Performed under the guidance of orthopaedic surgeons Mark Blyth, M.D., Bryn
Jones, M.D., Angus Maclean, M.D, and Iain Anthony, Ph.D., and Phil Rowe,
Ph.D., at the Glasgow Royal Infirmary and the University of Strathclyde, in
Glasgow, Scotland, the trial compared implant placement accuracy in patients
receiving MAKO's RESTORIS^® MCK implants using MAKO's RIO^® Robotic Arm
Interactive Orthopedic System to patients receiving manual placement of the
Oxford^® Partial Knee implant from Biomet Orthopedics. One hundred patients
have been enrolled in the study and randomly assigned (50 MAKO vs. 50 Oxford)
to receive UKA with or without the aid of robotic arm assistance. The
three-month results from 50 patients in each group also assessed early
clinical outcomes such as patient reported post-operative pain levels and
satisfaction. It is anticipated the trial will ultimately have 75 patients in
each group. The patients will be tracked for ten years post-operatively.

"The early results are encouraging, as the data show more accurate component
placement, as well as considerably lower self-reported post-operative pain
levels out to six weeks," said Dr. Blyth. "The early results suggest that
robotic arm assisted UKA with the RIO system greatly enhances the accuracy of
implant placement, which can be achieved with only minimal deviation from the
pre-operative plan."

Poor implant positioning in UKA is associated with suboptimal functional
outcome following surgery^1; however, robotic arm technology for UKA provides
pre-operative surgical planning for more accurate and minimal bone resection
(excision of part of the bone), and intra-operative joint balancing for
improved post-operative function and kinematics.

The primary endpoint of the clinical study is to validate the intra-operative
implant alignment values recorded by the RIO system and to compare the
accuracy of this implant positioning using robotic arm assistance with that
achieved using conventional instrumentation in a randomized cohort. Among the
secondary endpoints, the trial also examines early post-operative pain, and
initial results show a reduction in patient reported post-op pain, which
persists for almost 90 days following surgery. This ongoing trial will assess
patient clinical, psychological and functional outcomes pre-operatively and at
three months, one year, two years, five years and ten-years post-operatively.

"We are very happy with the early results for this randomized clinical trial,
as it demonstrates the effectiveness of our RIO system and MAKOplasty^®
Partial Knee Resurfacing as a minimally invasive surgical option for patients
with early to mid-stage osteoarthritis," said Maurice R. Ferré, M.D.,
president and chief executive officer of MAKO. "Results also suggest that
robotic arm assisted surgery for UKA may improve recovery with regard to less
pain immediately following the procedure. We believe these early results
underscore the importance of accuracy and precision in UKA surgeries, and the
benefits that MAKOplasty can provide surgeons and their patients."

About MAKOplasty

MAKO's RIO Robotic Arm Interactive Orthopedic System coupled with its
proprietary RESTORIS family of implants, enable surgeons to perform MAKOplasty
for knee resurfacing and total hip arthroplasty. The RIO system overcomes
limitations of conventional arthroplasty by providing auditory, visual and
tactile guidance that, when integrated with the touch and feel of the
surgeon's skilled hand, provide consistently reproducible precision in partial
knee resurfacing and total hip replacements. This advanced treatment option is
designed to relieve pain and restore range of motion for adults living with
osteoarthritis and other degenerative hip diseases.

About MAKO Surgical Corp.

MAKO Surgical Corp. is a medical device company that markets its RIO
Robotic-Arm Interactive Orthopedic system, with specific applications for
partial knee resurfacing and total hip replacement, and proprietary RESTORIS
Family of Implants for orthopedic procedures called MAKOplasty. The RIO is a
surgeon-interactive tactile surgical platform that incorporates a robotic arm
and patient-specific visualization technology, which enables accurate,
consistently reproducible bone resection for accurate insertion and alignment
of RESTORIS knee and hip implants. The MAKOplasty solution incorporates
technologies enabled by an intellectual property portfolio including more than
300 U.S. and foreign, owned and licensed, patents and patent applications.
Additional information can be found at www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other
things, statements related to expectations, goals, plans, objectives and
future events. MAKO intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained in Section
21E of the Securities Exchange Act of 1934 and the Private Securities Reform
Act of 1995. In some cases, forward-looking statements can be identified by
the following words: "may," "will," "could," "would," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "continue," "ongoing," or the negative of these terms or other
comparable terminology, although not all forward-looking statements contain
these words. These statements are based on the current estimates and
assumptions of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances, assumptions and
other factors that may cause actual results to differ materially from those
indicated by forward-looking statements, many of which are beyond MAKO's
ability to control or predict. Such factors, among others, may have a material
adverse effect on MAKO's business, financial condition and results of
operations and may include the potentially significant impact of a continued
economic downturn or delayed economic recovery on the ability of MAKO's
customers to secure adequate funding, including access to credit, for the
purchase of MAKO's products or cause MAKO's customers to delay a purchasing
decision, changes in general economic conditions and credit conditions,
changes in the availability of capital and financing sources for our company
and our customers, unanticipated changes in the timing of the sales cycle for
MAKO's products or the vetting process undertaken by prospective customers,
changes in competitive conditions and prices in MAKO's markets, changes in the
relationship between supply of and demand for our products, fluctuations in
costs and availability of raw materials and labor, changes in other
significant operating expenses, slowdowns, delays, or inefficiencies in MAKO's
product research and development cycles, unanticipated issues relating to
intended product launches, decreases in sales of MAKO's principal product
lines, decreases in utilization of MAKO's principal product lines or in
procedure volume, increases in expenditures related to increased or changing
governmental regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or foreign
regulatory requirements related to MAKO's current products, including
initiating and communicating product actions or product recalls and meeting
Medical Device Reporting requirements and other required reporting to the
United States Food and Drug Administration, or securing regulatory clearance
or approvals for new products or upgrades or changes to MAKO's current
products, developments adversely affecting our potential sales activities
outside the United States, increases in cost containment efforts by group
purchasing organizations, the impact of the United States healthcare reform
legislation enacted in March 2010 on hospital spending, reimbursement,
unanticipated changes in reimbursement to our customers for our products, and
the taxing of medical device companies, any unanticipated impact arising out
of the securities class action or any other litigation, inquiry, or
investigation brought against MAKO, loss of key management and other personnel
or inability to attract such management and other personnel, increases in
costs of retaining a direct sales force and building a distributor network,
unanticipated issues related to, or unanticipated changes in or difficulties
associated with, the recruitment of agents and distributors of our products,
and unanticipated intellectual property expenditures required to develop,
market, and defend MAKO's products. These and other risks are described in
greater detail under Item 1A, "Risk Factors," in MAKO's periodic filings with
the Securities and Exchange Commission, including MAKO's annual report on Form
10-K for the year ended December 31, 2012 filed on February 28, 2013. Given
these uncertainties, undue reliance should not be placed on these
forward-looking statements. MAKO does not undertake any obligation to release
any revisions to these forward-looking statements publicly to reflect events
or circumstances after the date of this press release or to reflect the
occurrence of unanticipated events.

"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo, whether
standing alone or in connection with the words "MAKO Surgical Corp." are
trademarks of MAKO Surgical Corp.

Oxford® is a registered trademark of Biomet Orthopedics

^1 Collier WB, Engh CA, McAuley JP, et al. Factors associated with the loss of
thickness of polyethylene tibial bearings after knee arthroplasty. J Bone
Joint Surg Am 2007;89:1306.

CONTACT: Media Contacts:
         Amy Cook
         925.552.7893
         amycook@amcpublicrelations.com
        
         Sue Siebert
         954.628.0804
         ssiebert@makosurgical.com
 
Press spacebar to pause and continue. Press esc to stop.